Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow.

eLife - 5 Sept 2024

Gerlevik Sila, Seymen Nogayhan, Hama Shan, Mumtaz Warisha, Thompson I Richard, Jalili Seyed R, Kaya Deniz E, Iacoangeli Alfredo, Pellagatti Andrea, Boultwood Jacqueline, Napolitani Giorgio, Mufti Ghulam J, Karimi Mohammad M

Abstract excerpt

Mutational profiles of myelodysplastic syndromes (MDS) have established that a relatively small number of genetic aberrations, including SF3B1 and SRSF2 spliceosome mutations, lead to specific phenotypes and prognostic subgrouping. We performed a multi-omics factor analysis (MOFA) on two published MDS cohorts of bone marrow mononuclear cells (BMMNCs) and CD34 + cells with three data modalities (clinical,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inflammation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Retroelements

Share to RNA Splicing Factors

Share to Serine-Arginine Splicing Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 39235452
DOI: 10.7554/eLife.97096
PMCID: PMC11377035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow.PMID 39235452Read ↗

Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrowSemantic proximity Read ↗

Inflammatory Signatures in MDS: The Missing Link Between Genetics, Microenvironment and TherapySemantic proximity Read ↗

Inflammatory Signatures in MDS: The Missing Link Between Genetics, Microenvironment, and Therapy.Semantic proximity Read ↗

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease processSemantic proximity Read ↗

Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.Semantic proximity Read ↗

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromesSemantic proximity Read ↗

Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.Semantic proximity Read ↗

Have we reached a molecular era in myelodysplastic syndromes?Semantic proximity Read ↗

Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification.Semantic proximity Read ↗

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.Semantic proximity Read ↗

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.